Braidwell LP Invests $34.02 Million in Maze Therapeutics, Inc. $MAZE

Braidwell LP acquired a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 1,140,040 shares of the company’s stock, valued at approximately $34,019,000. Maze Therapeutics makes up about 1.3% of Braidwell LP’s holdings, making the stock its 29th largest position. Braidwell LP owned 2.05% of Maze Therapeutics at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $133,502,907. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the second quarter valued at approximately $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics in the second quarter worth approximately $104,525,000. Jupiter Topco LLC bought a new position in shares of Maze Therapeutics in the second quarter worth approximately $101,764,000. Finally, Janus Henderson Group PLC increased its stake in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter.

Maze Therapeutics Stock Up 0.7%

Shares of MAZE opened at $26.72 on Thursday. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.60 and a beta of 2.17. Maze Therapeutics, Inc. has a 1 year low of $14.16 and a 1 year high of $53.65. The business’s 50 day simple moving average is $28.76 and its 200-day simple moving average is $31.34. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, equities analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,610 shares of company stock valued at $3,264,381 over the last 90 days. 5.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on MAZE. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.